How to Get Praluent (Alirocumab) in Vermont

Who Can Prescribe Praluent in Vermont

Any licensed prescriber with active prescriptive authority in Vermont can write a Praluent prescription. That includes physicians (MD and DO), nurse practitioners (NPs with full practice authority under Vermont's independent-practice statute), and physician assistants (PAs practicing under a collaborative agreement). Vermont is a full-practice-authority state for NPs, meaning no physician supervision requirement exists for APRN prescribing 1.

Cardiologists and endocrinologists prescribe Praluent most frequently, but primary care clinicians initiate it too, especially after two or more statins have failed or caused intolerable side effects. The 2018 ACC/AHA cholesterol guideline recommends PCSK9 inhibitor therapy when LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe in patients with established ASCVD [2]. For heterozygous familial hypercholesterolemia (HeFH), the Endocrine Society recommends PCSK9 inhibitors when LDL-C targets are not met despite high-intensity statin and ezetimibe combination therapy 3.

Vermont has roughly 2,400 active primary care physicians and over 1,100 NPs. Access is not limited to Burlington. Clinicians in Rutland, Brattleboro, St. Johnsbury, and Bennington can prescribe and manage alirocumab just as effectively, provided they can document the clinical criteria insurers require.

Telehealth Prescribing for Praluent in Vermont

Vermont law permits prescribing alirocumab through telehealth. The state's telemedicine parity statute (18 V.S.A. § 9361) requires private insurers to cover telehealth visits at the same rate as in-person encounters, making virtual lipid-management consultations a reimbursable pathway to Praluent access.

A telehealth visit for Praluent initiation typically lasts 20 to 30 minutes. The prescriber reviews your lipid history, confirms statin intolerance or inadequate LDL-C reduction, and orders any outstanding labs. You do not need to be physically present in a clinic. Vermont allows patients to connect from home, which matters in a rural state where the nearest lipid specialist may be 60 or more miles away.

HealthRX connects Vermont patients with licensed clinicians who prescribe PCSK9 inhibitors through synchronous video visits. After the visit, the prescriber submits the prior authorization and routes the prescription to a specialty pharmacy that ships directly to your Vermont address.

One practical note: Vermont does not require an initial in-person visit before telehealth prescribing for established patient-provider relationships. New patients can start via telehealth if the clinician determines adequate clinical information is available, which usually means recent labs and medical records from a prior provider.

Labs Required Before Starting Praluent

Prescribers in Vermont will order a fasting lipid panel before writing the Praluent prescription. This is both a clinical necessity and an insurance requirement. The panel must show the baseline LDL-C level that justifies PCSK9 inhibitor therapy.

Standard pre-treatment labs include:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides). Most insurers require results from within the past 4 to 12 weeks.
• Hepatic function panel (ALT, AST). The Praluent prescribing information lists no hepatic contraindication, but baseline liver enzymes are standard practice before adding a lipid-lowering agent [4].
• Creatine kinase (CK), if the patient reports prior statin-associated myalgia. This documents the muscle-related statin intolerance that justifies switching to a non-statin agent.
• Lp(a), recommended by the 2022 ACC Expert Consensus Decision Pathway. Elevated lipoprotein(a) above 50 mg/dL adds an independent ASCVD risk factor that strengthens the clinical rationale for PCSK9 inhibitor use 5.

Vermont has LabCorp and Quest Diagnostics draw sites in Burlington, South Burlington, Rutland, and Williston. Patients in the Northeast Kingdom or other rural areas can use hospital-affiliated outpatient labs at Northeastern Vermont Regional Hospital (St. Johnsbury) or North Country Hospital (Newport). Lab results from any CLIA-certified facility are acceptable for prior authorization submissions.

Vermont Medicaid Coverage and Prior Authorization

Vermont Medicaid (Green Mountain Care) covers Praluent with prior authorization. The PA process requires the prescriber to document three things: the diagnosis (HeFH or clinical ASCVD), failure of or intolerance to maximally tolerated statin therapy, and a recent LDL-C value showing persistent elevation despite optimized background therapy.

The specific documentation a Vermont Medicaid PA typically requires:

1. Diagnosis code: E78.01 (familial hypercholesterolemia) or a qualifying ASCVD ICD-10 code (I25.10, I63.9, I73.9, etc.)
2. Statin trial history: names, doses, durations, and reasons for discontinuation of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg)
3. Ezetimibe trial or contraindication: documentation that ezetimibe was added and LDL-C remained above target, or a reason ezetimibe was not used
4. Recent fasting lipid panel: showing LDL-C at or above 70 mg/dL (ASCVD) or at or above 100 mg/dL (primary prevention with HeFH)
5. Prescriber attestation: confirming the patient will receive injection training and has a follow-up lipid panel scheduled at 4 to 12 weeks

Vermont Medicaid decisions typically arrive within 72 hours for standard requests. Urgent PAs can be processed within 24 hours.

For commercial insurers operating in Vermont (Blue Cross Blue Shield of Vermont, MVP Health Care, Cigna), the PA requirements are similar. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P=0.0003) in post-acute coronary syndrome patients already on high-intensity statins 6. Insurers reference this evidence when establishing their coverage criteria.

Dr. Jennifer Robinson, principal investigator of several PCSK9 inhibitor trials, has stated: "PCSK9 inhibitors fill a critical gap for patients who cannot reach LDL-C goals with statins alone, particularly those with recent acute coronary syndromes where residual cholesterol risk remains high" 6.

How to Fill a Praluent Prescription in Vermont

Praluent is classified as a specialty medication. Most retail pharmacies (CVS, Walgreens, Rite Aid) do not stock it on the shelf, but their affiliated specialty pharmacy divisions can order and dispense it. The most common fulfillment pathways in Vermont are:

Specialty pharmacy mail-order. After the PA is approved, the prescriber routes the Rx to a specialty pharmacy (Accredo, CVS Specialty, AllianceRx Walgreens Prime, or Optum Specialty). The pharmacy ships the Praluent pen or syringe in a temperature-controlled package directly to your Vermont address. Standard shipping takes 3 to 5 business days. Cold-chain integrity is maintained with gel packs, and shipments include a temperature monitor strip.

503A compounding pharmacies. Vermont licenses 503A compounding pharmacies that can dispense patient-specific prescriptions. While alirocumab itself is a biologic (a monoclonal antibody) and cannot be traditionally compounded, 503A pharmacies may serve as dispensing intermediaries for specialty medications under certain state board of pharmacy provisions. Confirm with the Vermont Board of Pharmacy whether a specific 503A pharmacy in the state handles PCSK9 inhibitor dispensing.

In-office administration. Some cardiology and lipid clinics in Burlington and surrounding areas stock Praluent for first-dose administration in the office. This lets a nurse demonstrate proper subcutaneous injection technique. Subsequent doses are then filled through specialty pharmacy.

The 2023 ACC/AHA guidelines note that medication adherence with PCSK9 inhibitors improves when patients receive hands-on injection training at initiation 2. Vermont prescribers can bill CPT 96372 for the in-office injection and G0463 for the injection training at hospital outpatient settings.

Timeline from First Visit to First Injection

The typical timeline for a Vermont patient starting Praluent runs 2 to 4 weeks from the initial prescriber visit to the first self-administered dose at home. Here is the breakdown.

Week 1. Telehealth or in-person evaluation. The clinician orders labs (if not already available) and reviews your statin history. If labs are already on file, the PA submission can happen the same day.

Week 1 to 2. Labs drawn and resulted. The prescriber submits the prior authorization to your insurer or Vermont Medicaid. Standard PA turnaround is 48 to 72 hours. If denied, a peer-to-peer review or formal appeal adds 5 to 14 days.

Week 2 to 3. PA approved. The specialty pharmacy receives the prescription, verifies insurance, and contacts you to confirm the shipping address and schedule delivery.

Week 3 to 4. Praluent arrives at your door in cold-chain packaging. You administer the first injection (abdomen, thigh, or upper arm) and schedule a follow-up lipid panel for 4 to 12 weeks post-initiation.

Patients with urgent clinical need (recent ACS, LDL-C above 190 mg/dL) may qualify for expedited PA and bridge supply programs through Regeneron's MyPraluent support program.

Cost and Financial Assistance in Vermont

Praluent's wholesale acquisition cost (WAC) runs approximately $450 to $500 per month before insurance. After commercial insurance with an approved PA, out-of-pocket costs vary by plan but commonly fall between $0 and $150 per month with manufacturer copay assistance.

Regeneron MyPraluent Copay Card. Eligible commercially insured patients may pay as little as $0 per fill. The program covers up to a set annual maximum.

Vermont Medicaid. Copays for preferred specialty drugs on Green Mountain Care are capped at nominal amounts (often $1 to $3 per fill), making Praluent accessible even for income-limited patients once the PA is approved.

Patient assistance programs (PAPs). Uninsured or underinsured Vermont patients can apply through Regeneron's patient assistance program. Eligibility generally requires household income at or below 400% of the federal poverty level.

A 2019 analysis published in JAMA Cardiology found that PCSK9 inhibitor net prices declined by approximately 60% from their 2015 launch price following payer negotiations and manufacturer rebates 7. The improved cost-effectiveness ratio (estimated at $85,000 per QALY at net price vs. $350,000+ at list price) contributed to broader payer acceptance.

Clinical Evidence Supporting Alirocumab Use

The evidence base for alirocumab centers on the ODYSSEY trial program. ODYSSEY OUTCOMES, a randomized controlled trial of 18,924 patients with recent acute coronary syndrome, demonstrated that alirocumab reduced the composite of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by 15% versus placebo over a median 2.8 years of follow-up 6.

The trial's prespecified mortality analysis showed a nominal reduction in all-cause death (3.5% vs. 4.1%, HR 0.85 to 95% CI 0.73 to 0.98), though this did not meet the hierarchical testing threshold for statistical significance 6.

The 2018 AHA/ACC multisociety guideline on blood cholesterol management recommends PCSK9 inhibitors as add-on therapy for patients with clinical ASCVD and LDL-C at or above 70 mg/dL on maximally tolerated statin plus ezetimibe 2. The 2022 ACC Expert Consensus update reaffirmed this recommendation and expanded the emphasis on PCSK9 inhibitors for very high-risk patients, including those with multiple prior events or polyvascular disease 5.

Dr. Gregory Schwartz, ODYSSEY OUTCOMES steering committee member, noted: "The absolute benefit of alirocumab was greatest in patients with baseline LDL-C of 100 mg/dL or higher, where the number needed to treat to prevent one event over 4 years was approximately 16" 6.

Alirocumab has a well-characterized safety profile across the ODYSSEY program. Injection-site reactions occurred in 3.8% of patients versus 2.1% on placebo. Neurocognitive events were evaluated in the ODYSSEY OUTCOMES neurocognitive substudy (N=2,603) and showed no significant difference between alirocumab and placebo groups 8.

Transferring a Praluent Prescription to Vermont

If you are relocating to Vermont with an active Praluent prescription from another state, the transfer process is straightforward. Your new Vermont prescriber (or your existing prescriber, if licensed in Vermont) can issue a new prescription or your current specialty pharmacy can coordinate a state-to-state transfer if they operate in both jurisdictions.

You will need to provide your new Vermont clinician with recent labs, the current PA approval letter, and documentation of your statin history. Most Vermont insurers will honor an active PA from a prior plan for up to 90 days during a transition period, but this varies by carrier. Confirming with your new insurer before the move prevents supply gaps.

Specialty pharmacies that operate nationally (Accredo, CVS Specialty) can often update the shipping address without requiring a new prescription, as long as the prescriber's DEA and state license cover the patient's new location. Alirocumab is not a controlled substance, which simplifies the transfer logistics.